Intellikine has initiated a multicentre Phase I dose escalation study of INK1117 in patients with advanced solid malignancies.

INK1117 is a selective, orally available, small molecule inhibitor of the PI3Kalpha isoform.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Phase I study is intended to evaluate the safety, tolerability and pharmacokinetic profile of the PI3Kalpha selective inhibitor.

In PI3Kalpha mutant-specific preclinical tumour models, INK1117 has demonstrated good efficacy results.

Vall d’Hebron University Hospital, Barcelona, Medical Oncology Department head Josep Tabernero said they will explore INK1117 in cancer patients, particularly those whose tumours have a mutation of the PIK3CA gene.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact